AcelRx Pharmaceuticals, Inc. (ACRX) News

AcelRx Pharmaceuticals, Inc. (ACRX): $1.00

-0.02 (-1.96%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ACRX News Items

ACRX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ACRX News Highlights

  • For ACRX, its 30 day story count is now at 5.
  • Over the past 16 days, the trend for ACRX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • LAW, MCG and MCS are the most mentioned tickers in articles about ACRX.

Latest ACRX News From Around the Web

Below are the latest news stories about Acelrx Pharmaceuticals Inc that investors may wish to consider to help them evaluate ACRX as an investment opportunity.

AcelRx Pharmaceuticals to Participate in Two September Investor Conferences

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will be providing an overview of the business and company updates at the H.C. Wainwright & Co. 23rd Annual Global Investment Conference taking place September 13-15, 2021, and at the Cantor Fitzgerald Virtual Global Healthcare Conference taking place September 27

Yahoo | September 10, 2021

Lifshitz Law Firm, P.C. Announces Investigations of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Frequency Therapeutics, Inc. (NasdaqGS: FREQ), RLX Technology Inc. (NYSE: RLX), and Washington Prime Group, Inc. (NYSE: WPG)

NEW YORK, NY / ACCESSWIRE / August 30, 2021 / Lifshitz Law Firm, P. (NASDAQ:ACRX)Lifshitz Law Firm, P.

Yahoo | August 30, 2021

Study Results Announced During Award-Winning Presentation on the Effect of Sufentanil Sublingual Tablet on Outpatient Plastic Surgery at the Annual Miami Cosmetic Surgery Event

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the results of a study evaluating sufentanil sublingual tablet 30 mcg (SST) for outpatient plastic surgery that was presented during the Miami Cosmetic Surgery (MCS) conference on Friday, August 27th at the Miami Beach Convention Center in Miami Beach, Florida.

Yahoo | August 30, 2021

Presentation on the Effect of the Administration of Sufentanil Sublingual Tablet on Reducing Post-Operative Recovery Time and Opioid Use in Plastic Surgery at the Annual Miami Cosmetic Surgery Event

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced an upcoming presentation on the effects of administering sufentanil sublingual tablet 30 mcg (SST) at Miami Cosmetic Surgery held at the Miami Beach Convention Center in Miami Beach, Florida from August 25-27, 2021.

Yahoo | August 26, 2021

Understanding AcelRx Pharma’s Risk Factors Post Q2

AcelRx Pharmaceuticals,Inc. (ACRX) is focused on bringing to market therapies for moderate-to-severe acute pain. Its DSUVIA (called DZUVEO in Europe) is targeted for managing acute pain. Its second product, Zalviso is being developed in the U.S. as a patient-controlled analgesia system to reduce moderate-to-severe pain in medically supervised settings. Both DSUVIA and Zalviso have received approval in Europe. The company's recent Q2 performance fell short of expectations on the revenue front. Earnings, on the other hand, were in line with consensus.

Kailas Salunkhe on TipRanks | August 25, 2021

21 Stocks Moving in Thursday's Pre-Market Session

Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares rose 86.5% to $1.39 in pre-market trading after dropping 12% on Wednesday. Sonnet BioTherapeutics recently reported its financial results for the three months ended June 30th , 2021 and issued a business update. Eros STX Global Corporation (NYSE: ESGC) rose 32% to $0.87 in pre-market trading. Eros STX Global shares jumped around 28% on Wednesday following a Deadline report titled 'Eros STX And Amazon Prime Video Expand Output De

Yahoo | August 19, 2021

Thinking about buying stock in NanoVibronix, Advanced Micro Devices, Romeo Power, Futu Holdings, or AcelRx Pharmaceuticals?

NEW YORK , Aug. 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NAOV, AMD, RMO, FUTU, and ACRX. Full story available on Benzinga.com

Benzinga | August 17, 2021

AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Lags Revenue Estimates

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0.00% and -19.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 16, 2021

AcelRx Pharmaceuticals Reports Second Quarter 2021 Financial Results

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its second quarter 2021 financial results.

Yahoo | August 16, 2021

Moore Kuehn, PLLC Encourages Investors of ACRX to Contact Law Firm

New York, New York--(Newsfile Corp. - August 12, 2021) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating potential claims involving directors and officers regarding possible breaches of fiduciary duties related to whether insiders caused their companies to make false and/or misleading statements and/or failed to disclose, among other things, that:AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)The company or its officers and directors made false and/or misleading sta

Yahoo | August 12, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6851 seconds.